Document Detail


Factors affecting the pharmacokinetics after living donor liver transplant.
MedLine Citation:
PMID:  23023417     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Fifty-five thousand organ transplants are performed each year around the world. It is now estimated that over 300000 organ transplant recipients are alive worldwide. Most of these transplant recipients will remain on immunosuppressive drugs for the remainder of their lives to prevent rejection episodes. Doses of these medications must be judiciously managed to optimize patient outcomes. Subtherapeutic drug concentrations may lead to graft rejection and subsequent graft loss. Supratherapeutic drug concentrations increase the likelihood of drug toxicities and increase the likelihood of opportunistic infections. In this review, the latest reports concerning the factors affecting the pharmacokinetics of tacrolimus and micafungin after living donor liver transplant (LDLT) are summarized. Our experimental results demonstrate that preoperative assessment of cytochrome P450 3A5 (CYP3A5) genotypes in both recipients and donors and an immune cell function assay would be useful not only for predicting tacrolimus pharmacokinetics but also for defining groups at high-risk of infectious complications after LDLT. Finally, monitoring plasma trough micafungin concentrations allows safe and effective dose titration of micafungin in LDLT-recipients with total bilirubin concentrations greater than 5 mg/dL.
Authors:
Yuichi Muraki
Related Documents :
23221167 - Obesity and kidney transplant candidates: how big is too big for transplantation?.
24347577 - Fetal striatal grafting slows motor and cognitive decline of huntington's disease.
6456127 - Hydroxyproline turnover in dermal collagen grafts in reconstituted skin wounds in the rat.
23065527 - The combination of siromilus plus tacrolimus improves outcome after reduced-intensity c...
16615417 - Correction factors after having neglected the first exponential in the estimation of ch...
6326927 - Analysis and management of renal failure in fourth mrc myelomatosis trial. mrc working ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan     Volume:  132     ISSN:  1347-5231     ISO Abbreviation:  Yakugaku Zasshi     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0413613     Medline TA:  Yakugaku Zasshi     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  1011-7     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Mie University Hospital.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Study on the discovery of novel chitinase inhibitors based on natural products.
Next Document:  Evaluation for antithrombotic agents by a thrombotic model in animals.